Moderna Stock Analysis

Moderna Stock Analysis Notes

About 74.0% of the company shares are owned by institutional investors. The book value of Moderna was now reported as 36.27. The company recorded a loss per share of 12.33. Moderna had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of August 2017. Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3700 people. To find out more about Moderna contact Stephane Bancel at 617 714 6500 or learn more at https://www.modernatx.com.

Moderna Investment Alerts

Moderna Upcoming and Recent Events

Moderna Largest EPS Surprises

View All Earnings Estimates

Moderna Stock Institutional Investors

Note, although Moderna's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Moderna Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 41.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Moderna Profitablity

The company has Profit Margin (PM) of (0.69) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average.

Management Efficiency

Moderna has return on total asset (ROA) of (0.1197) % which means that it has lost $0.1197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2859) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Moderna's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Other Current Assets are forecasted to decline to about 83.6 M.

Technical Drivers

As of the 29th of April, Moderna secures the Risk Adjusted Performance of 0.0367, downside deviation of 2.78, and Mean Deviation of 2.48. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moderna, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Moderna, which can be compared to its peers in the industry. Please verify Moderna coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Moderna is priced some-what accurately, providing market reflects its recent price of 107.97 per share. Given that Moderna has jensen alpha of (0.02), we recommend you to check Moderna's last-minute market performance to make sure the company can sustain itself at a future point.

Moderna Price Movement Analysis

Moderna Insider Trading Activities

Moderna Predictive Daily Indicators

Moderna Corporate Filings

Moderna Forecast Models

Moderna's time-series forecasting models are one of many Moderna's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moderna's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Moderna prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Moderna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Moderna. By using and applying Moderna Stock analysis, traders can create a robust methodology for identifying Moderna entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moderna analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moderna analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Moderna stock analysis indicators help investors evaluate how Moderna stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Moderna shares will generate the highest return on investment. By understating and applying Moderna stock analysis, traders can identify Moderna position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.

Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.